Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.670 -0.020 (-1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 456,961
Open 1.700
Bid (Size) 1.660 (5,100)
Ask (Size) 1.670 (2,400)
Prev. Close 1.690
Today's Range 1.630 - 1.780
52wk Range 0.4350 - 3.040
Shares Outstanding 85,029,042
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Century Therapeutics Appoints Joseph Truitt to Board of Directors
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+67.9%
+67.9%
1 Month
-22.0%
-22.0%
3 Month
-28.0%
-28.0%
6 Month
-17.3%
-17.3%
1 Year
+242.4%
+242.4%

More News

Read More
News headline image
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics (NASDAQ:IPSC) Reports Narrower Loss, Extended Cash Runway to 2029 ↗
Via Chartmill
News headline image
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Century Therapeutics Reports First Quarter Financial Results and Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Participate in Upcoming Investor Conferences in March
From Century Therapeutics, Inc.
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Reports Flat Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Century Therapeutics, Inc. - Common Stock publicly traded?
Yes, Century Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Century Therapeutics, Inc. - Common Stock trade on?
Century Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Century Therapeutics, Inc. - Common Stock?
The ticker symbol for Century Therapeutics, Inc. - Common Stock is IPSC on the Nasdaq Stock Market
What is the current price of Century Therapeutics, Inc. - Common Stock?
The current price of Century Therapeutics, Inc. - Common Stock is 1.670
When was Century Therapeutics, Inc. - Common Stock last traded?
The last trade of Century Therapeutics, Inc. - Common Stock was at 09/25/26 04:00 PM ET
What is the market capitalization of Century Therapeutics, Inc. - Common Stock?
The market capitalization of Century Therapeutics, Inc. - Common Stock is 142.00M
How many shares of Century Therapeutics, Inc. - Common Stock are outstanding?
Century Therapeutics, Inc. - Common Stock has 142M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.